Heart valve health, disease, replacement, and repair: a 25-year cardiovascular pathology perspective

Cardiovascular Pathology

Volumn 25, Issue 4, 2016, Pages 341-352

  Schoen, Frederick J ^a,b   Gotlieb, Avrum I ^c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bioprosthesis; Calcification; Extracellular matrix; Fibrosis; Mechanical valve; Tissue engineering; Valve endocardial cell; Valve interstitial cell

Indexed keywords

AORTA VALVE DISEASE; BIOMECHANICS; BLEEDING; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); ENDOCARDIUM; ENGINEERED TISSUE; HEART MYXOMA; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; NONHUMAN; PATHOLOGIST; PATHOLOGY; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROSTHESIS THROMBOSIS; PROSTHETIC VALVE ENDOCARDITIS; REVIEW; VALVE DETERIORATION; VALVULAR HEART DISEASE; VALVULOPLASTY; ANIMAL; CARDIOLOGY; PROCEDURES; TRENDS;

ANIMALS; CARDIOLOGY; HEART VALVE DISEASES; HUMANS;

EID: 84969974937     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2016.05.002     Document Type: Review

References (168)

1. [1] Iung, B, Vahanian, A, Epidemiology of acquired valvular heart disease. Can J Cardiol 30 (2014), 962–970.
2. [2] Sharma, S, Mehra, A, Rahimtoola, SH, Valvular heart disease: a century of progress. Am J Med 121 (2008), 664–673.
3. [3] Chaikof, EL, The development of prosthetic heart valves–lessons in form and function. N Engl J Med 357 (2007), 1368–1371.
4. [4] Schoen, FJ, Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation 118 (2008), 1864–1880.
5. [5] Schoen, FJ, Mechanisms of function and disease of natural and replacement heart valves. Annu Rev Pathol 7 (2012), 161–183.
6. [6] Liu, AC, Joag, VR, Gotlieb, AI, The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 171 (2007), 1407–1418.
7. [7] Li, C, Xu, S, Gotlieb, AI, The progression of calcific aortic valve disease through injury, cell dysfunction, and disruptive biology and physical force feedback loops. Cardiovasc Pathol 22 (2013), 1–8.
8. [8] Ayoub, S, Ferrari, G, Gorman, RC, Gorman, JH, Schoen, FJ, Sacks, MS, Heart valve biomechanics and underlying mechanobiology. Compr Physiol, 2016 [in press].
9. [9] Wang, H, Leinwand, LA, Anseth, KS, Cardiac valve cells and their microenvironment-insights from the vitro studies. Nat Rev Cardiol 11 (2014), 715–727.
10. [10] Stephens, EH, Shangkuan, J, Kuo, JJ, Carroll, JL, Kearney, DL, Carberry, KE, et al. Extraceullar matrix remodeling and cell phenotypic changes in dysplastic and hemodynamically altered semilunar human cardiac valves. Cardiovasc Pathol 20 (2011), e157–e167.
11. [11] Yap, CH, Kim, HS, Balachandran, K, Weiler, M, Haj-Ali, R, Yoganathan, AP, Dynamic deformation characteristics of porcine aortic valve leaflet under normal and hypertensive conditions. Am J Physiol Heart Circ Physiol 298 (2010), H395–H405.
12. [12] Aikawa, E, Whittaker, P, Farber, M, Mendelson, K, Padera, RF, Aikawa, M, et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation 113 (2006), 1344–1352.
13. [13] Rajamannan, NM, Subramaniam, M, Springett, M, Sebo, TC, Niekrasz, M, McConnell, JP, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105 (2002), 2660–2665.
14. [14] Cheek, JD, Wirrig, EE, Alfieri, CM, James, JF, Yutzey, KE, Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease. J Mol Cell Cardiol 52 (2012), 689–700.
15. [15] Sider, KL, Zhu, C, Kwong, Mirzaei, Z, de Langé, CF, Simmons, CA, Evaluation of a porcrine model of early aortic valve sclerosis. Cardiovasc Pathol 23 (2014), 289–297.
16. [16] Bowler, MA, Merryman, WD, In vitro models of aortic valve calcification: solidifying a system. Cardiovasc Pathol 24 (2015), 1–10.
17. [17] Shapero, K, Wylie-Sears, J, Levine, RA, Mayer, JE, Bischoff, J, Reciprocal interactions between mitral valve endothelial and interstitial cells reduce endothelial-to-mesenchymal transition and myofibroblastic activation. J Mol Cell Cardiol 80 (2015), 175–185.
18. [18] Wirrig, EE, Yutzey, KE, Transcriptional regulation of heart valve development and disease. Cardiovasc Pathol 20 (2011), 162–167.
19. [19] Liebner, S, Cattelino, A, Gallini, R, Rudini, N, Iurlaro, M, Piccolo, S, Dejana, E, β-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol 166 (2004), 359–367.
20. [20] Timmerman, LA, Grego-Bessa, J, Raya, A, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformations. Genes Dev 18 (2004), 99–115.
21. [21] Alfieri, CM, Cheek, J, Chakraborty, S, Yutzey, KE, Wnt signaling in heart valve development and osteogenic gene induction. Dev Biol 338 (2010), 127–135.
22. [22] Hurlstone, AF, Haramis, AP, Wienholds, E, Begthel, H, Korving, J, Van Eeden, F, et al. The Wnt/beta-catenin pathway regulates cardiac valve formation. Nature 425 (2003), 633–637.
23. [23] Lee, MP, Ratner, N, Yutzey, KE, Genome-wide Twist1 occupancy in endocardial cushion cells, embryonic limb buds, and peripheral nerve sheath tumor cells. Genomics 15 (2014), 821–835.
24. [24] Lee, MP, Yutzey, KE, Twist1 directly regulates genes that promote cell proliferation and migration in developing heart valves. PLoS One, 6, 2011, e29758.
25. [25] de la Pompa, JL, Timmerman, LA, Takimoto, H, Yoshida, H, Elia, AJ, Samper, E, et al. Role of NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 392 (1998), 182–186.
26. [26] Ranger, AM, Grusby, MJ, Gravallese, EM, de la Brousse, FC, Hoey, T, Mickanin, C, et al. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 392 (1998), 186–190.
27. [27] Lincoln, J, Alfieri, CM, Yutzey, KE, BMP and FGF regulatory pathways control cell lineage diversification of heart valve precursor cells. Dev Biol 292 (2006), 290–302.
28. [28] Zhao, B, Etter, L, Hinton, RB, Benson, DW, BMP and FGF regulatory pathways in semilunar valve precursor cells. Dev Dyn 236 (2007), 971–980.
29. [29] Lincoln, J, Kist, R, Scherer, G, Yutzey, KE, Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol 305 (2007), 120–132.
30. [30] Peacock, JD, Levay, AK, Gillaspie, DB, Tao, G, Lincoln, J, Reduced sox9 function promotes heart valve calcification phenotypes in vivo. Circ Res 106 (2010), 712–719.
31. [31] LaHaye, S, Lincoln, J, Garg, V, Genetics of valvular heart disease. Curr Cardiol Rep 16 (2014), 487–496.
32. [32] Parakash, SK, Bosse, Y, Muehlschlegel, JD, Michelena, HI, Limongelli, G, Della Corte, A, et al. A roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: insights from the international BAVCon (bicuspid aortic valve consortium). J Am Coll Cardiol 64 (2014), 832–839.
33. [33] Delling, FN, Vasan, RS, Epidemiology and pathophysiology of mitral valve prolapse. New insights into disease progression, genetics and molecular basis. Circulation 129 (2014), 2158–2170.
34. [34] Lincoln, J, Garg, V, Etiology of valvular heart disease. Genetic and developmental origins. Circ J 78 (2014), 1801–1807.
35. [35] Garg, V, Muth, AN, Ransom, JF, Schluterman, MK, Barnes, R, King, IN, et al. Mutations in NOTCH1 cause aortic valve disease. Nature 437 (2005), 270–274.
36. [36] Padang, R, Bagnall, RD, Richmond, DR, Bannon, PG, Semsarian, C, Rare non-synonymous variations in the transcriptional activation domains of GATA5 in bicuspid aortic valve disease. J Mol Cell Cardiol 53 (2012), 277–281.
37. [37] Jondeau, G, Boileau, C, Genetics of thoracic aortic aneurysms. Curr Atheroscler Rep 14 (2012), 219–226.
38. [38] Rizzo, S, Basso, C, Lazzarini, E, Celeghin, R, Paolin, A, Gerosa, G, et al. TGF-beta1 pathway activation and adherens junction molecular pattern in nonsyndromic mitral valve prolapse. Cardiovasc Pathol 24 (2015), 359–367.
39. [39] Balachandran, K, Sucosky, P, Jo, H, Yoganathan, AP, Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. Am J Physiol Heart Circ Physiol 296 (2009), H756–H764.
40. [40] Rodgers, LS, Lalani, S, Hardy, KM, Xiang, X, Broka, D, Antin, PB, et al. Depolymerized hyaluronan induces vascular endothelial growth factor, a negative regulator of developmental epithelial-to-mesenchymal transformation. Circ Res 99 (2006), 583–589.
41. [41] Norris, RA, Moreno-Rodriguez, RA, Sugi, Y, Sugi, Y, Hoffman, S, Amos, J, Har, MM, et al. Periostin regulates atrioventricular valve maturation. Dev Biol 316 (2008), 200–213.
42. [42] Fayet, C, Bendeck, MP, Gotlieb, AI, Cardiac valve interstitial cells secrete fibronectin and form fibrillary adhesions in response to injury. Cardiovasc Pathol 16 (2007), 203–211.
43. [43] Li, C, Xu, S, Gotlieb, AI, The response to valve injury. A paradigm to understand the pathogenesis of heart valve disease. Cardiovasc Pathol 20 (2011), 183–190.
44. [44] Stephens, EH, Kearney, DL, Grande-Allen, KJ, Insight into pathologic abnormalities in congenital semilunar valve disease based on advances in understanding normal valve microstructure and extracellular matrix. Cardiovasc Pathol 21 (2012), 46–58.
45. [45] Butcher, JT, Tressel, S, Johnson, T, Turner, D, Sorescu, G, Jo, H, et al. Transcriptional profiles of valvular and vascular endothelial cell reveal phenotypic differences: influence of shear stress. Arterioscler Thromb Vasc Biol 26 (2006), 69–77.
46. [46] Butcher, JT, Penrod, AM, Garcia, AJ, Nerem, RM, Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments. Arterioscler Thromb Vasc Biol 24 (2004), 1429–1434.
47. [47] Simmons, CA, Grant, GR, Manduchi, E, Davies, PF, Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res 96 (2005), 792–796.
48. [48] Carruthers, CA, Alfieri, CM, Joyce, EM, Watkins, Sc, Yutzey, KE, Sacks, MS, Gene expression and collagen fiber micromechanical interactions of the semilunar heart valve interstitial cell. Cell Mol Bioeng 5 (2012), 254–265.
49. [49] Lee, CH, Carruthers, CA, Avoub, S, Gorman, RC, Gorman, JH, Sacks, MS, Quantification and simulation of layer-specific mitral valve interstitial cells deformation under physiological loading. J Theor Biol 373 (2015), 26–39.
50. [50] Liu, AC, Gotlieb, AI, Transforming growth factor-β regulates in vitro heart valve repair by activated valve interstitial cells. Am J Pathol 173 (2008), 1275–1285.
51. [51] Durbin, A, Nadir, NA, Rosenthal, A, Gotlieb, AI, Nitric oxide promotes in vitro interstitial cell heart valve repair. Cardiovasc Pathol 14 (2005), 12–18.
52. [52] Li, C, Gotlieb, AI, Transforming growth factor-β regulates the growth of valve interstitial cells in vitro. Am J Pathol 179 (2011), 1746–1755.
53. [53] Han, L, Gotlieb, AI, Fibroblast growth factor-2 promotes in vitro mitral valve interstitial cell repair through transforming growth factor-β/Smad signaling. Am J Pathol 178 (2011), 119–127.
54. [54] Han, L, Gotlieb, AI, Fibroblast growth factor-2 promotes in vitro heart valve interstitial cell repair through the Akt1 pathway. Cardiovasc Pathol 21 (2012), 382–389.
55. [55] Chen, JH, Chen, WL, Sider, KL, Yip, YC, Simmons, CA, β-catenin mediates mechanically regulated, transforming growth factor β-1-induced myofibroblast differentiation of aortic valve interstitial cells. Arterioscler Thromb Vasc Biol 31 (2011), 590–597.
56. [56] Xu, S, Gotlieb, AI, Wnt3a/β-catenin increases proliferation in heart valve interstitial cells. Cardiovasc Pathol 22 (2013), 156–166.
57. [57] Psaltis, PJ, Zannettino, A, Worthley, SG, Gronthos, S, Mesenchymal stromal cells—potential for cardiovascular repair. Stem Cells Express 26 (2008), 2201–2210.
58. [58] Camenisch, TD, Schroeder, JA, Bradley, J, Klewer, SE, Caplice, N, Bone marrow–derived myofibroblasts are present in adult human heart valves. J Heart Valve Dis 14 (2005), 674–678.
59. [59] Chen, JH, Yip, CY, Sone, ED, Simmons, CA, Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am J Pathol 174 (2009), 1109–1119.
60. [60] Fang, M, Alfieri, CM, Hulin, A, Conway, SJ, Yutzey, KE, Loss of β-catenin promotes chondrogenic differentiation of aortic valve interstitial cells. Arteriolscler Thromb Vasc Biol 34 (2014), 2601–2608.
61. [61] Hjortnaes, J, Shapero, K, Goettsch, C, Hutcheson, JD, Keegan, J, Kluin, J, et al. Valvular interstitial cells suppress calcification of valvular endothelial cells. Atherosclerosis 242 (2015), 251–260.
62. [62] Otto, CM, Prendergast, DM, Aortic-valve stenosis – from patients at risk to severe valve obstruction. N Engl J Med 371 (2014), 744–756.
63. [63] Mozaffarian, D, Benjamin, EJ, Go, AS, Arnett, DK, Blaha, MJ, Cushman, M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133 (2015), e38–e360.
64. [64] Hutcheson, JD, Aikawa, E, Merryman, WD, Potential drug targets for calcific aortic valve disease. Nat Rev Cardiol 11 (2014), 218–231.
65. [65] Xu, S, Liu, AC, Gotlieb, AI, Common pathogenic features of atherosclerosis and calcific aortic stenosis: role of transforming growth factor-beta. Cardiovasc Pathol 19 (2010), 1275–1285.
66. [66] Thanassoulis, G, Campbell, CY, Owens, DS, Smith, JG, Smith, AV, Peloso, GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 368 (2013), 503–512.
67. [67] Lindman, BR, Bonow, RO, Otto, CM, Current management of cardiac aortic stenosis. Circ Res 113 (2013), 223–237.
68. [68] Rajamannan, NM, Evans, FJ, Aikawa, E, Grande-Allen, KJ, Demer, LL, Heistad, DD, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart Lung and blood institute aortic stenosis working group. Circulation 124 (2011), 1783–1791.
69. [69] Arsenault, BJ, Boekholdt, SM, Dubé, MP, Rhéaume, E, Wareham, NJ, Khaw, KT, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case–control cohort. Circ Cardiovasc Genet 7 (2014), 304–310.
70. [70] Chan, KL, Teo, K, Dumesnil, JG, Ni, A, Tam, J, ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 121 (2010), 306–314.
71. [71] Cowell, SJ, Newby, DE, Prescott, RJ, Bloomfield, P, Reid, J, Northridge, DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005), 2389–2397.
72. [72] Rossebo, AB, Pedersen, TR, Boman, K, Brudi, P, Chambers, JB, Egstrup, K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359 (2008), 1343–1356.
73. [73] Latif, N, Quillon, A, Sarathchandra, P, McCormack, A, Lozanoski, A, Yacoub, MH, et al. Modulation of human valve interstitial cell phenotype and function using a fibroblast growth factor 2 formulation. PLoS One, 10, 2015, e0127844.
74. [74] Torre, M, Hwang, D, Padera, RF, Mitchell, RN, VanderLaan, PA, Osseous and chondromatous metaplasia in calcific aortic stenosis. Cardiovasc Pathol 25 (2016), 18–24.
75. [75] Gould, ST, Srigunapalan, S, Simmons, CA, Anseth, KS, Hemodynamic and cellular response feedback in calcific aortic valve disease. Circ Res 113 (2013), 186–197.
76. [76] Merryman, WD, Lukoff, HD, Long, RA, Engelmayr, GC, Hopkins, RA, Sacks, MS, Synergistic effects of cyclic tension and transforming growth factor β1 on the aortic valve myofibroblast. Cardiovasc Pathol 16 (2007), 268–276.
77. [77] Mathieu, P, Bouchareb, R, Boulanger, MC, Innate and adaptive immunity in calcific aortic valve disease. J Immunol Res, 2015, 2015, 851945.
78. [78] Jung, JJ, Razavian, M, Challa, AA, Nie, L, Golestani, R, Zhang, J, et al. Multimodality and molecular imaging of matrix metalloproteinase activation in calcific aortic valve disease. J Nucl Med 56 (2015), 933–938.
79. [79] Yoshioka, M, Yuasa, S, Matsumura, K, Kimura, K, Shiomi, T, Kimura, N, et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med 12 (2006), 1151–1159.
80. [80] Hakuno, D, Kimura, N, Yoshioka, M, Fukuda, K, Role of angiogenetic factors in cardiac valve homeostasis and disease. J Cardiovasc Transl Res 4 (2011), 727–740.
81. [81] Goettsch, C, Hutcheson, JD, Aikawa, E, MicroRNA in cardiovascular calcification. Focus on targets and extracellular vesicle delivery mechanism. Circ Res 112 (2013), 1073–1084.
82. [82] Dweck, MR, Khaw, HJ, Sng, GKZ, Luo, ELC, Baird, A, Williams, MC, et al. Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation?. Eur Heart J 34 (2013), 1567–1574.
83. [83] Rabkin, E, Aikawa, M, Stone, JR, Fukumoto, Y, Libby, P, Schoen, FJ, Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 104 (2001), 2525–2532.
84. [84] Dina, C, Bouatia-Naji, N, Tucker, N, Delling, FN, Toomer, K, Durst, R, et al. Genetic association analyses highlight biological pathways underlying mitral valve prolapse. Nat Genet 47 (2015), 1206–1211.
85. [85] Hulin, A, Deroanne, C, Lambert, C, Defraigne, J-O, Nusgens, B, Radermecker, M, et al. Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data. Cardiovasc Pathol 22 (2013), 245–250.
86. [86] Levine, RA, Hagege, AA, Judge, DP, et al. Mitral valve disease – morphology and mechanisms. Nat Rev Cardiol 12 (2015), 689–710.
87. [87] Cook, JR, Carta, L, Galatioto, J, Ramirez, F, Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes. Clin Genet 87 (2015), 11–20.
88. [88] Chaudhry, SS, Cain, SA, Morgan, A, et al. Fibrillin-1 regulates the bioavailability of TFGbeta1. J Cell Biol 176 (2007), 355–367.
89. [89] Bertoli-Avella, AM, Gillis, E, Morisaki, H, et al. Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol 65 (2015), 1324–1336.
90. [90] Ng, CM, Cheng, A, Myers, LA, et al. TGF-β-dependent pathogenesis of mitral valve prolapsed in a mouse model of Marfan syndrome. J Clin Invest 114 (2004), 1543–1592.
91. [91] Smith, LB, Hadoke, PWF, Dyer, E, et al. Haploinsufficiency of the murine Col3a1 locus causes aortic dissection: a novel model of the vascular type of Ehlers-Danlos syndrome. Cardiovasc Res 90 (2011), 182–190.
92. [92] Pepin, MG, Schwarze, U, Rice, KM, et al. Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). Genet Med 16 (2014), 881–888.
93. [93] Norris, RA, Moreno-Rodgrigues, R, Wessels, A, et al. Expression of the familiar cardiac valvular dystrophy gene, filamin-a, during heart morphogenesis. Dev Dyn 239 (2010), 2118–2127.
94. [94] Huang, G, Rahimtoola, SH, Prosthetic heart valve. Circulation 123 (2011), 2602–2605.
95. [95] Nishimura, RA, Otto, CM, Bonow, RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 63 (2014), e57–e185.
96. [96] Yanagowa, B, Christakis, GT, Bioprosthetic aortic valve replacement: stented pericardial and porcine valves. Cohn, L.H., (eds.) Cardiac surgery in the adult, 4th ed., 2012, 695 [New York, McGraw Hill].
97. [97] Gallegos, RP, Gudbjartsson, T, Aranki, S, Mitral valve replacement. Cohn, L.H., (eds.) Cardiac Surgery in the Adult, 2012, 849 [New York, McGraw Hill].
98. [98] Schoen, FJ, Butany, J, Cardiac valve replacement and related interventions. Buja, L.M., Butany, J., (eds.) Cardiovascular pathology, 4th ed., 2015, Elsevier, 529–576.
99. [99] Kheradvar, A, Groves, EM, Goergen, C, Alavi, H, Tranquillo, R, et al. Emerging trends in heart valve engineering: part II. Novel and standard technologies for aortic valve replacement. Ann Biomed Eng 43 (2015), 844–857.
100. [100] Hammermeister, KE, Sethi, GK, Henderson, WG, Grover, FL, Oprian, C, Rahimtoola, SH, Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve. Final report of the veterans affairs randomized trial. J Am Coll Cardiol 36 (2000), 1152–1158.
101. [101] Oxenham, H, Bloomfield, P, Wheatley, DJ, Lee, RJ, Cunningham, J, Prescott, RJ, et al. Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. Heart 89 (2003), 715–721.
102. [102] Daneshvar, SA, Rahimtoola, SH, Valve prosthesis-patient mismatch (VP-PM): a long-term perspective. J Am Coll Cardiol 60 (2012), 1123–1135.
103. [103] Lengvel, M, Diagnosis and treatment of left-sided prosthetic valve thrombosis. Expert Rev Cardiovasc Ther 6 (2008), 85–93.
104. [104] Iung, B, Rodes-Cabau, J, The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties. Eur Heart J 35 (2014), 2942–2949.
105. [105] Roca, B, Roca, M, The new oral anticoagulants: reasonable alternatives to warfarin. Cleve Clin J Med 82 (2015), 847–854.
106. [106] Chambers, JB, Pomar, JL, Mestres, CA, Palatianos, GM, Clinical event rates with the on-X bileaflet mechanical heart valve: a multicenter experience with follow-up to 12 years. J Thorac Cardiovasc Surg 145 (2013), 420–424.
107. [107] O'Connor, CT, Kiernan, TJ, Contemporary management of prosthetic valve endocarditis: principles and future outlook. Expert Rev Cardiovasc Ther 13 (2015), 501–510.
108. [108] Schaff, HV, Carrel, TP, Jamieson, WR, Jones, KW, Rufilanchas, J, Cooley, DA, et al. Paravalvular leak and other events in silzone-coated mechanical heart valves: a report from AVERT. Ann Thor Surg 73 (2002), 785–792.
109. [109] Harrison, DC, Ibrahim, MA, Weyman, AE, Kuller, LH, Blot, WJ, Miller, DE, The Bjork-Shiley convexo-concave heart valve experience from the perspective of the supervisory panel. Am J Cardiol 112 (2013), 1921–1931.
110. [110] Schoen, FJ, Levy, RJ, Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg 79 (2005), 1072–1080.
111. [111] Valente, M, Bortolotti, U, Thiene, G, Ultrastructural substrates of dystrophic calcification in porcine bioprosthetic valve failure. Am J Pathol, 119, 1985, 12.
112. [112] Bailey, MT, Pillarisetti, S, Xiao, H, Vyavahare, NR, Role of elastin in pathologic calcification of xenograft heart valves. J Biomed Mater Res 66 (2003), 93–102.
113. [113] Sacks, MS, Schoen, FJ, Collagen fiber disruption occurs independent of calcification in clinically explanted bioprosthetic heart valves. J Biomed Mater Res 62 (2002), 359–371.
114. [114] Shah, SR, Vyavahare, NR, The effect of glycosaminoglycan stabilization on tissue buckling in bioprosthetic heart valves. Biomaterials 29 (2008), 1645–1653.
115. [115] Gammie, JS, Sheng, S, Griffith, BP, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons adult cardiac surgery database. Ann Thorac Surg 87 (2009), 1431–1439.
116. [116] Brown, JM, O'Brien, SM, Wu, C, Sikora, JAH, Griffith, BP, Gammie, JS, Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg 137 (2009), 82–90.
117. [117] Flameng, W, Rega, F, Vercalsteren, M, Herijgers, P, Meuris, B, Antimineralization treatment and patient-prosthesis mismatch are major determinants of the onset and incidence of structural valve degeneration in bioprosthetic heart valves. J Thorac Cardiovasc Surg 147 (2014), 1219–1224.
118. [118] Senage, T, Le Tourneau, S, Foucher, Y, Pattier, S, Cueff, C, Michel, M, et al. Early structural valve deterioration of Mitroflow aortic bioprosthesis. Mode, incidence, and impact on outcome in a large cohort of patients. Circulation 130 (2014), 2012–2020.
119. [119] Sherrah, AG, Edelman, JJ, Thomas, SR, Brady, PW, Wilson, MK, Jeremy, RW, et al. The freestyle aortic bioprosthesis: a systematic review. Heart Lung Circ 23 (2014), 1110–1117.
120. [120] Butany, J, Collins, MJ, Nair, V, Leask, RL, Scully, HE, Williams, WG, et al. Morphological findings in explanted Toronto stentless porcine valves. Cardiovasc Pathol 15 (2006), 41–48.
121. [121] Nair, V, Law, KB, Li, AY, Phillips, RB, David, TE, Butany, J, Characterizing the inflammatory reaction in explanted Medtronic freestyle stentless porcine aortic bioprosthesis over a 6-year period. Cardiovasc Pathol 21 (2012), 158–168.
122. [122] Mitchell, RN, Jonas, RA, Schoen, FJ, Pathology of explanted cryopreserved allograft heart valves: comparison with aortic valves from orthotopic heart transplants. J Thorac Cardiovasc Surg 115 (1998), 118–127.
123. [123] Bansal, N, Kumar, SR, Baker, CJ, Lemus, R, Wells, WJ, Starnes, VA, Age-related outcomes of the Ross procedure over 20 years. Ann Thorac Surg 99 (2015), 2077–2085.
124. [124] David, TE, Ross procedure at the crossroads. Circulation 119 (2009), 207–209.
125. [125] Rabkin-Aikawa, E, Aikawa, M, Farber, M, Kratzz, JR, Garcia-Cardena, G, Touchoukos, NT, et al. Clinical pulmonary autograft valves: pathological evidence of adaptive remodeling in the aortic site. J Thorac Cardiovasc Surg 128 (2004), 552–556.
126. [126] Bezuidenhout, D, Williams, DF, Zilla, P, Polymeric heart valves for surgical implantation, catheter-based technologies and heart assist devices. Biomaterials 36 (2015), 6–25.
127. [127] Claibome, TE, Slepian, MJ, Hossainy, S, Bluestein, D, Polymeric trileaflet prosthetic heart valves: evolution and path to clinical reality. Expert Rev Med Devices 9 (2012), 577–594.
128. [128] Meuris, B, Flameng, WJ, Laborde, F, Folliguet, TA, Haverich, A, Shrestha, M, Five-year results of the pilot trial of a sutureless valve. J Thorac Cardiovasc Surg 150 (2015), 84–88.
129. [129] Di Eusanio, M, Phan, K, Sutureless aortic valve replacement. Am Cardiothorac Surg 4 (2015), 123–130.
130. [130] Cribier, A, Eltchaninoff, H, Bash, A, Boenstein, N, Tron, C, Bauer, F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106 (2002), 3006–3008.
131. [131] Adams, DH, Popma, JJ, Reardon, MJ, Yakubov, SJ, Coselli, JS, Deeb, GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370 (2014), 1790–1798.
132. [132] Mack, MJ, Leon, MB, Smith, CR, Miller, DG, Moses, JW, Tuzcu, EM, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385 (2015), 2477–2484.
133. [133] Kapadia, SR, Leon, MB, Makkar, RR, Tuzcu, EM, Svensson, LG, Kodali, S, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperative aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385 (2015), 2485–2491.
134. [134] Bourantas, CV, Serruys, PW, Evolution of transcatheter aortic valve replacement. Circ Res 114 (2014), 1037–1051.
135. [135] Law, KB, Phillips, KR, Butany, J, Pulmonary valve-in-valve implants: how long do they prolong reintervention and what causes them to fail?. Cardiovasc Pathol 21 (2012), 519–521.
136. [136] Dvir, D, Barbanti, M, Tan, J, Webb, JG, Transcatheter aortic valve-in-valve implantation for patients with degenerative surgical bioprosthetic valves. Curr Probl Cardiol 39 (2014), 7–27.
137. [137] Fishbein, GA, Schoen, FJ, Fishbein, MC, Transcatheter aortic valve implantation: status and challenges. Cardiovasc Pathol 23 (2014), 65–70.
138. [138] Fassa, AA, Himbert, D, Vahanian, A, Mechanisms and management of TAVR-related complications. Nat Rev Cardiol 10 (2013), 685–696.
139. [139] Mylotte, D, Andalib, A, Theriault-Lauzier, P, Dorfmeister, M, Girgis, M, Alharbi, W, et al. Transcatheter heart valve failure: a systematic review. Eur Heart J 36 (2015), 1306–1327.
140. [140] Makkar, RR, Fontana, G, Jilaihawi, H, Chakravarty, T, Kofoed, KF, de Backer, O, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373 (2015), 2015–2024.
141. [141] Beohar, N, Kirtane, AJ, Blackstone, E, Waksman, R, Holmes, D, Minha, S, et al. Trends in complications and outcomes of patients undergoing transfemoral transcatheter aortic valve replacement. JACC Cardiovasc Interv, 2016.
142. [142] Puri, R, Rodes-Cabau, J, Transcatheter aortic valve replacement. A revolution in evolution. JACC Cardiovasc Interv, 2016 [in press].
143. [143] Cheatham, JP, Hellenbrand, WE, Zahn, EM, Jones, TK, Berman, DP, Vincent, JA, et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replaement in the US melody valve investigational device exemption trial. Circulation 131 (2015), 1960–1970.
144. [144] Schoen, FJ, Heart valve tissue engineering: quo vadis?. Curr Opin Biotechnol 22 (2011), 698–705.
145. [145] Bouten, CV, Driessen-Mol, A, Baaijens, FP, In situ heart valve tissue engineering: simple devices, smart materials, complex knowledge. Expert Rev Med Devices 9 (2012), 453–455.
146. [146] Kheradvar, A, Groves, EM, Dasi, LP, Alavi, SH, Tranquillo, R, Grande-Allen, KJ, et al. Emerging trends in heart valve engineering: part 1. Solutions for future. Ann Biomed Eng 43 (2015), 833–843.
147. [147] Kurobe, H, Maxfield, MW, Breuer, CK, Shinoka, T, Concise review: tissue-engineered vascular grafts for cardiac surgery: past, present, and future. Stem Cell Transl Med 1 (2012), 566–571.
148. [148] Hoerstrup, SP, Sodian, R, Daebritz, S, et al. Functional living trileaflet heart valves grown in-vitro. Circulation, 102, 2000 [III-44 – III-49].
149. [149] Cheung, DY, Duan, B, Butcher, JT, Current progress in tissue engineering of heart valves: multiscale problems, multiscale solutions. Expert Opin Biol Ther 15 (2015), 1155–1172.
150. [150] Lueders, C, Jastram, B, Hetzer, R, Schwandt, H, Rapid manufacturing techniques for the tissue engineering of human heart valves. Eur J Cardiothorac Surg 46 (2014), 593–601.
151. [151] Zhang, X, Xu, B, Puperi, DS, Yonezawa, AL, Wu, Y, Tseng, H, et al. Integrating valve-inspired design features into poly(ethylene glycol) hydrogel scaffolds for heart valve tissue engineering. Acta Biomater 14 (2015), 11–21.
152. [152] Alavi, SH, Kheradvar, A, A hybrid tissue-engineered heart valve. Ann Thorac Surg 99 (2015), 2183–2187.
153. [153] Masoumi, N, Annabi, N, Assmann, A, Larson, BL, Hjortnaes, J, Alemdar, N, et al. Tri-layered elastomeric scaffolds for engineering heart valve leaflets. Biomaterials 35 (2014), 7774–7785.
154. [154] Matheny, RG, Hutchison, ML, Dryden, PE, Hiles, MD, Shaar, CJ, Porcine small intestine submucosa as a pulmonary valve leaflet substitute. J Heart Valve Dis 9 (2000), 769–774.
155. [155] Ghazanfari, S, Driessen-Mol, A, Sanders, B, Dijkman, PE, Hoerstrup, SP, Baaijens, FPT, et al. In vivo collagen remodeling in the vascular wall of decellularized stented tissue-engineered heart valves. Tissue Eng A 21 (2015), 2206–2215.
156. [156] Nakayama, Y, Takewa, Y, Sumikura, H, Yamanami, M, Matsui, Y, Oie, T, et al. In-body tiddue-engineered aortic vavle (Biovalve type VII) architecture based on 3D printer molding. J Biomed Mater Res B Appl Biomater 103 (2015), 1–11.
157. [157] Emmert, MY, Weber, B, Falk, V, Hoerstrup, SP, Transcatheter tissue engineered heart valves. Expert Rev Med Devices 11 (2014), 15–21.
158. [158] Driessen-Mol, A, Emmert, MY, Dijkman, PE, Frese, L, Sanders, B, Weber, B, et al. Transcatheter implantation of homologous “off-the-shelf” tissue-engineered heart valves with self-repair capacity: long-term functionality and rapid in vivo remodeling in sheep. J Am Coll Cardiol 63 (2014), 1320–1329.
159. [159] Di Bardino, D, El Bardissi, A, McClure, S, Razo-Vasquez, OA, Kelly, NE, Cohn, LH, Four decades experience with mitral valve repair: analysis of differential indications, technical evolution, and long term outcome. J Thorac Cardiovasc Surg 139 (2010), 76–84.
160. [160] Boodhwani, M, El Khoury, G, Aortic valve repair: indications and outcomes. Curr Cardiol Rep, 16, 2014, 490.
161. [161] Luk, A, Rao, V, Cusimano, RJ, David, TE, Butany, J, CorMatrix extracellular matrix used for valve repair in the adult: is there de novo valvular tissue seen?. Ann Thorac Surg 99 (2015), 2205–2207.
162. [162] Luk, A, Butany, J, Ahn, E, Fann, JI, St Goar, F, Thornton, T, et al. Mitral repair with the Evalve MitraClip device: histopathologic findings in the porcine model. Cardiovasc Pathol 18 (2009), 279–285.
163. [163] Schoen, FJ, Hoffman, AS, Implant and device failure. Ratner, B.D., Hoffman, A.S., Schoen, F.J., Lemons, J.E., (eds.) Biomaterials science: an introduction to materials in medicine, 3rd ed., 2012, Academic Press/Elsevier, 1361.
164. [164] Anderson, JM, Schoen, FJ, Brown, SA, Merritt, K, Implant retrieval and evaluation. Ratner, B.D., Hoffman, A.S., Schoen, F.J., Lemons, J.E., (eds.) Biomaterials science: an introduction to materials in medicine, 3rd ed., 2012, Academic Press/Elsevier, 1368.
165. [165] Schoen, FJ, Approach to analysis of cardiac valve prostheses as surgical pathology or autopsy specimens. Cardiovasc Pathol 4 (1995), 241–255.
166. [166] Butany, J, Ahluwalia, MS, Munroe, C, Fayet, C, Ahn, C, Blit, P, et al. Mechanical heart valve prostheses: identification and evaluation. Cardiovasc Pathol 12 (2003), 322–344.
167. [167] Butany, J, Fayet, C, Ahluwalia, MS, Blit, P, Ahn, C, Munroe, C, et al. Biological replacement heart valves. Identification and evaluation. Cardiovasc Pathol 12 (2003), 119–139.
168. [168] Silver, MD, Late complications of prosthetic heart valves. Arch Pathol Lab Med 102 (1978), 281–284.